Parexel International ((PRXL)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Parexel International, in collaboration with ALK-Abelló A/S, is conducting a significant clinical study titled A Phase I/II Trial in 3 Parts Assessing the Safety, Tolerability, and Efficacy of a Once-daily Peanut Sublingual Immunotherapy (SLIT) Tablet in Adults, Adolescents, and Children With Peanut Allergy. The study aims to evaluate the safety, tolerability, and efficacy of a peanut SLIT-tablet in individuals with peanut allergies, which is crucial for developing effective allergy treatments.
The intervention being tested is a biological treatment known as the Peanut SLIT-tablet, designed to desensitize individuals to peanut allergens and reduce allergic reactions.
This interventional study employs a randomized, parallel assignment model with a quadruple masking approach. It is structured in three parts: dose determination, tolerability assessment, and efficacy evaluation, focusing primarily on treatment purposes.
The study began on September 7, 2022, and is currently active but not recruiting participants. The last update was submitted on June 27, 2025. These dates are critical for tracking the study’s progress and anticipated outcomes.
The study’s progress could influence the stock performance of ALK-Abelló A/S and Parexel, as successful results may enhance their market position in allergy treatments. Investors should monitor this study’s developments, considering the competitive landscape of allergy therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.